Introduction

Sexually transmitted infections (STIs) remain a global public health problem. The World Health Organization (WHO) estimates that about 500 million new STIs occur annually among people aged between 15 and 49 years.1 In sub-Saharan Africa, the incidence of STIs among population aged between 15 and 49 years is about 240/1000 which is the highest record in the world.1 It is estimated that about 8.3, 21.1 and 59.7 million new cases of Chlamydia trachomatis, Neisseria gonorrhoea and Trichomonas vaginalis infections, respectively, occur in sub-Saharan Africa annually. N. gonorrhoea, C. trachomatis and T. vaginalis have been found to increase human immunodeficiency virus (HIV)
acquisition and transmission. In Mwanza Tanzania, the prevalence of \textit{N. gonorrhoea} among adult patients attending care and treatment clinics (CTC) using polymerase chain reaction (PCR) was reported to be 2%.\textsuperscript{3} Moreover, a study which was done in 10 different antenatal clinics in Mwanza, Tanzania among adolescent pregnant women showed that 199 (49.4%) had at least one STI.\textsuperscript{4} The prevalence of STIs among HIV women opting for intrauterine contraceptive device (IUCD) in Uganda was reported to be 5.9%.\textsuperscript{5}

Approximately, 160 million women worldwide use IUCD making it the most popular contraceptive method after sterilization.\textsuperscript{6} The use of IUCD in the city of Mwanza with an estimated population of 1.2 million people has been found to increase in the past 3 years. It was noted that in 2014, 2015 and 2016, a total of 11,170, 12,292 and 14,807 women opted IUCD use, respectively.\textsuperscript{7–9} In an asymptomatic woman, the placement of IUCD can result in the transmission of pathogens responsible for STIs into the uterine cavity leading to development of pelvic inflammatory disease (PID), chronic pelvic pain and infertility.\textsuperscript{10} PID-associated intrauterine contraception is the commonest in the first 20 days of intrauterine contraception initiation.\textsuperscript{11,12} The United States Center for Disease Control and Prevention (CDC) and WHO recommend women at high risk of STIs to undergo STIs screening before the placement of IUCD.\textsuperscript{13,14} However, in low- and middle-income countries (LMICs) such services are not readily available. Syndromic approach has been used to screen women before IUCD insertion, however, the approach has low sensitivity.\textsuperscript{15} Tanzania, like many other LMICs, the syndromic management for STIs is being implemented.\textsuperscript{14} Evidence shows that 30%–80% of the women with \textit{N. gonorrhoea}, 85% with \textit{C. trachomatis} and 80% with \textit{T. vaginalis} are asymptomatic.\textsuperscript{15} This indicates that a large number of women might be living with asymptomatic STIs.

STIs symptoms have low sensitivity and specificity in detecting STIs signifying the importance of STIs screening to detect STIs before IUCD insertion.\textsuperscript{16} Despite the fact that the prevalence of these infections is high in LMICs, there are limited number of studies that focused on women opting for IUCD use. In a view of this, this study investigated the presence of common STIs among women undergoing syndromic screening for STI prior to placement of IUCD. These findings are crucial in revising current protocol in LMICs in order to reduce IUCD associated morbidities.

Methods

**Study design, duration, target population and study area**

A cross-sectional health facility-based study was conducted between August and December 2017 in the city of Mwanza. Enrolment was done at Makongoro and Uzazi na Malezi bora Tanzania (UMATI) clinics. The total population served by these clinics is about 56,442 with approximately 500 IUCD insertions in a year. The study included family planning clinic attendees aged 18 years and above who opted for IUCD use.

**Sample size estimation and sampling technique**

The sample size was obtained by Kish Leslie formula using the prevalence of 5.9%.\textsuperscript{5} The minimum sample size was 85 women, however, a total of 150 women were enrolled. The study participants were enrolled conveniently until the sample size was reached.

**Selection criteria**

The study included women who were asymptomatic for STIs and seeking for IUCD placement service. Women who presented with signs and symptoms of STIs after physical examination (e.g. abnormal vaginal discharge purulent with yellow or brownish colour with foul-smelling, genital sores or blisters, painful intercourse, genital itching, lower abdominal pain, painful urination, pregnant women, those having gynaecological conditions such as cancer of the cervix, gestation trophoblastic disease, endometrial and ovarian cancer) as per national guidelines for management of sexually transmitted and reproductive tract infections were excluded. All women who tested positive were managed as per the Tanzania Standard Treatment Guidelines.\textsuperscript{17}

**Data/sample collection and sample processing**

Pre-tested structured questionnaire was used to collect socio-demographic and other relevant information such as education level, age, religion, marital status, participant’s alcohol use, disclosure of HIV status to partner, use of ARV, condom use, CD4 count, parity and number of sexual partners per year. About 4–5 mL of venous blood sample was collected aseptically from each consented participant and placed in plain vacutainer tubes (Becton Dickson and Company, Kenya). Sera were separated and stored at -80°C until processing.

Sera were used for detection of HSV-2 using immunochromatographic rapid tests as per manufacturer instructions (INVIBIO Biomaterials Solutions, Beijing, China). Detection of HIV 1 and 2 was done as per Tanzania protocol for HIV screening.\textsuperscript{18} For \textit{T. pallidum} (Syphilis) detection, a forward algorithm was used whereby a non-Treponemal test, \textit{T. pallidum} antibodies (ARKRAY Healthcare Pvt. Ltd., Surat, India) followed by a treponemal test and \textit{T. pallidum} hemagglutination test (TPHA) (Human Biochemical and Diagnostic, Wiesbaden, Germany) confirmation.

Endocervical swabs were collected and used to detect \textit{C. trachomatis} infections as detailed in the manufacturer’s instructions (INVIBIO Biotech Co Ltd, Beijing, China), with sensitivity detection of $10^6$ bacteria/ml and specificity of 97.5% to detect chlamydia antigen.
The Papanicolaou (PAP) smear was stained as previously described and examined under light microscope in low- and high-power objectives to observe pathological findings such as necrosis and presence of different inflammatory cells such as neutrophils, lymphocytes etc.

**Data analysis**

Data were collected and entered into computer Microsoft Excel 2007 and later analysed using STATA version 12. Continuous variables (age, gravidity etc.) were summarized using median with interquartile range (IQR) and categorical variables (residence, occupation marital status, etc.) were summarized as proportions. Test for association was done using chi- square test. Univariate and multivariate logistic regression model was used to determine independent predictors for STIs. A p-value of less than 0.05 at 95% confidence interval was considered statistically significant.

**Results**

**Sociodemographic characteristics of asymptomatic women opted for IUCD use**

A total of 150 asymptomatic women opted for IUCD placement were enrolled with the median age of 26 [IQR 23–32] years. The majority 129 (86.0%) aged between 18 and 35 years and most of them 144 (96.0%) were from urban areas. Three quarters 113 (75.3%) were Christians and more than three quarters 126 (84%) were married (Table 1).

**History of symptoms of STIs and sexual behaviours among women opted for IUCD use**

Lower abdominal pain 35/150 (23.3%), vaginal discharges 31/150 (20.7%) and dysuria 23/150 (15.3%) were reported as history (at least 3 months before seeking placement) of STIs symptoms. The most commonly reported high risk sexual behaviours were multiple sexual partners 28/150 (18.7%) (Table 2).

**Prevalence of specific STIs among asymptomatic women opted for IUCD use in Mwanza City**

Out of 150 enrolled asymptomatic women opted for IUCD use, the prevalence of HSV2 (HSV-2, IgM), T. pallidum and C. trachomatis were 3/115 (2.6%, 95% confidence interval (CI): 0.3–5.6), 8/150 (5.3%, 95% CI:1.7–9.0) and 34/150 (22.7%, 95% CI: 15.9–29.4), respectively. The overall prevalence of STIs was 45/150 (30.0%, 95% CI: 22.6–37.4). In addition, the sero-prevalence of specific HSV-2 IgG antibodies were found to be 34/150 (22.6%, 95% CI: 15.9–29.3). Among the participants, only (4%) were known to be HIV positive and were on antiretroviral therapy (ART).

**Cytological changes observed among women opted for IUCD use in Mwanza city**

Among cytological changes observed, the most common features were the presence of chronic inflammation indicated by the presence of lymphocytes which was observed in 56 (37.3%) women and acute inflammation as indicated by the presence of predominantly neutrophils which was observed in 14 (9.3%) women (Figure 1). However, none of the observed histopathological changes were found to be associated with any of studied STIs.

**Factors associated with active STIs among asymptomatic women opted for IUCD use in**

On univariate logistic regression analysis, history of vaginal discharge (odds ratio (OR) 2.8; 95% CI 1.2–6.3; p = 0.014),
The history of lower abdominal pain (OR 2.9; 95%CI 1.3–6.5; p=0.007), history of per vaginal bleeding (OR 10.1; 95%CI 1.1–93.3; p=0.041) were significantly associated with STIs among asymptomatic women opted for IUCD use. By multivariate logistic regression analysis, the odds of having history of dysuria (OR 6.6; 95%CI 2.3–18.8; p<0.001) and the odds of having a partner with history of STIs (OR 4.6; 95%CI 1.0–20.8; p=0.049) independently predicted the presence of active STIs among women opted for IUCD use in the city of Mwanza (Table 3).

### Table 2. History of symptoms of STIs and sexual behaviours among women opted for IUCD use in Mwanza city.

| Past symptoms                  | Number | Percent (%) |
|--------------------------------|--------|-------------|
| History of vaginal discharge   | Yes    | 31          | 20.7        |
|                                | No     | 119         | 79.3        |
| History of dysuria             | Yes    | 23          | 15.3        |
|                                | No     | 127         | 84.7        |
| History of lower abdominal pain| Yes    | 35          | 23.3        |
|                                | No     | 115         | 76.7        |
| History of dyspareunia         | Yes    | 17          | 11.3        |
|                                | No     | 133         | 88.7        |
| History of vaginal bleeding    | Yes    | 5           | 3.3         |
|                                | No     | 145         | 96.7        |
| History of discharge to partner| Yes    | 1           | 0.7         |
|                                | No     | 149         | 99.3        |
| History of multiple sex partner| Yes    | 28          | 18.7        |
|                                | No     | 122         | 81.3        |
| History of past STI infection  | Yes    | 11          | 7.3         |
|                                | No     | 139         | 92.7        |
| History of blisters            | Yes    | 18          | 12.0        |
|                                | No     | 132         | 88.0        |

### Discussion

This study has reported the burden of STIs among women opted for IUCD use in Mwanza, Tanzania, the overall prevalence of active STIs was 30.0% which is higher than two previous studies from East Africa. In the present study, *C. trachomatis* was the leading pathogen detected followed by *T. pallidum*. Regarding *T. pallidum*, the prevalence was comparable to a previous study among adolescent pregnant women in rural areas of Mwanza despite population differences implying the same magnitude of *T. pallidum* across different women population in the City of Mwanza. In comparison to a previous study in the northern region of Tanzania among pregnant women, the reported prevalence in the current study is significantly high. Variations in geographical distribution and risk factors among the study populations may explain observed differences.

Concerning HSV-2 acute infection, seroprevalence reported in the current study is almost similar to the recently published report among pregnant women in the rural areas of Mwanza. In comparison to IgG seroprevalence, the findings are comparable to studies in northern part of Tanzania and rural areas of Mwanza region. This could be explained by the fact that, the risk factors in the study areas could be the same. In the contrary, the IgG seroprevalence reported in this study is low compared to 87% reported in Mbeya. The
Table 3. Factors associated with active STIs among asymptomatic women opted for IUCD use in Mwanza city.

| Client characteristics       | STI                  |               | Univariate | Multivariate |               |               |
|------------------------------|----------------------|---------------|------------|--------------|---------------|---------------|
|                              | Yes | No | n (%) | n (%) | OR [95% CI] | p-value | OR [95% CI] | p-value |
| **Age in years**             |     |    |       |       |             |         |            |         |
| 18–35                        | 39  | 90 | (30.2) | (69.8) | 1.0         |          |             |         |
| >35                          | 6   | 15 | (28.6) | (71.4) | 0.9 [0.3–2.6] | 0.878   |             |         |
| **Residence**                |     |    |       |       |             |         |            |         |
| Urban                        | 42  | 102| (29.2) | (70.8) | 1.0         |          |             |         |
| Rural                        | 3   | 3  | (50.0) | (50.0) | 0.4 [0.1–2.1] | 0.289   |             |         |
| **Religion**                 |     |    |       |       |             |         |            |         |
| Christian                    | 37  | 53 | (32.7) | (46.9) | 1.0         |          |             |         |
| Muslim                       | 8   | 28 | (22.2) | (77.8) | 1.7 [0.7–4.1] | 0.234   |             |         |
| Others                       | 0   | 1  | (0.0)  | (100.0) |             |          |             |         |
| **Marital status**           |     |    |       |       |             |         |            |         |
| Not married                  | 7   | 17 | (29.2) | (70.8) | 1.0         |          |             |         |
| Married                      | 38  | 88 | (30.2) | (69.8) | 0.9 [0.4–2.5] | 0.923   |             |         |
| **Occupation**               |     |    |       |       |             |         |            |         |
| Employed                     | 1   | 7  | (12.5) | (87.5) | 1.0         |          |             |         |
| Self employed                | 3   | 18 | (14.3) | (85.7) | 1.2 [0.1–13.2] | 0.901   | 1.1 [0.1–15.7] | 0.936   |
| Business                     | 20  | 46 | (30.3) | (69.7) | 3.0 [0.4–26.4] | 0.313   | 4.0 [0.4–40.9] | 0.241   |
| Not employed                 | 21  | 34 | (38.2) | (61.8) | 4.3 [0.5–37.7] | 0.185   | 5.7 [0.5–58.7] | 0.145   |
| **Education level**          |     |    |       |       |             |         |            |         |
| Sec/collage                  | 14  | 39 | (26.4) | (73.6) | 1.0         |          |             |         |
| Illiterate/Primary           | 31  | 66 | (32.0) | (68.0) | 1.3 [0.6–2.8] | 0.479   |             |         |
| **Parity**                   |     |    |       |       |             |         |            |         |
| Null/Prime para              | 18  | 37 | (32.7) | (67.3) | 1.0         |          |             |         |
| Multi/Grand para             | 27  | 68 | (28.4) | (71.6) | 0.8 [0.4–1.7] | 0.579   |             |         |
| **Health facility**          |     |    |       |       |             |         |            |         |
| Butimba                      | 17  | 49 | (25.8) | (74.2) | 1.0         |          |             |         |
| Makongoro                    | 23  | 45 | (33.8) | (66.2) | 1.3 [0.7–3.1] | 0.309   |             |         |
| UMATI                        | 5   | 11 | (31.2) | (68.8) | 1.3 [0.4–4.3] | 0.657   |             |         |
| **Sex frequency**            |     |    |       |       |             |         |            |         |
| Once or not at all           | 8   | 17 | (22.0) | (78.0) | 1.0         |          |             |         |
| Twice or more/week           | 37  | 88 | (29.6) | (70.4) | 0.9 [0.4–2.3] | 0.811   |             |         |
| **H/vaginal discharge**      |     |    |       |       |             |         |            |         |
| No                           | 30  | 89 | (25.2) | (74.8) | 1.0         |          |             |         |
| Yes                          | 15  | 16 | (48.4) | (51.6) | 2.8 [1.2–6.3] | 0.014   |             |         |
| **History of dysuria**       |     |    |       |       |             |         |            |         |
| No                           | 30  | 97 | (23.6) | (76.4) | 1.0         |          |             |         |
| Yes                          | 15  | 8  | (65.2) | (34.8) | 6.1 [2.3–15.7] | <0.001 | 6.6 [2.3–18.8] | <0.001 |
| **H/lower abdominal pain**   |     |    |       |       |             |         |            |         |
| No                           | 28  | 87 | (24.3) | (75.7) | 1.0         |          |             |         |
| Yes                          | 17  | 18 | (48.6) | (51.4) | 2.9 [1.3–6.5] | 0.007   |             |         |
| **History of dyspareunia**   |     |    |       |       |             |         |            |         |
| No                           | 38  | 95 | (28.6) | (71.4) | 1.0         |          |             |         |
| Yes                          | 17  | 10 | (41.2) | (58.8) | 1.8 [0.6–4.9] | 0.290   |             |         |
| **H/vaginal bleeding**       |     |    |       |       |             |         |            |         |
| No                           | 41  | 1.4| (28.3) | (71.7) | 1.0         |          |             |         |
| Yes                          | 4   | 1  | (80.0) | (20.0) | 10 [1.1–93.5] | 0.041   | 5.5 [0.5–62.6] | 0.170   |
| **Discharge (sexual partner)**|     |    |       |       |             |         |            |         |
| No                           | 45  | 104| (30.2) | (69.8) | 1.0         |          |             |         |
| Yes                          | 0   | 1  | (0.0)  | (100.0) | Ommitted     |         |             |         |

(Continued)
Possible explanation could be differences in study population whereby the previous study enrolled bar attendants who were at higher risk of acquiring STIs than the participants in the current study.

Regarding *C. trachomatis*, in this study, the prevalence was significantly high compared to a similar study done in Uganda which reported a prevalence of 0.9% \(^5\) and low compared to a previous study in the same settings. \(^20\) This could be explained by the fact that the previous study focused on infertile women.

Factors associated with asymptomatic STIs among women opted for IUCD

Among the factors studied, history of dysuria in the last 3 months before seeking IUCD placement was found to predict STIs among women opted for IUCD use. Similar findings were also observed in previous studies in the USA and India whereby a significant proportion of women with different STIs presented with dysuria. \(^16,24\) This could be explained by the fact that dysuria has been reported as one of the commonest symptoms of STIs. \(^25\) History of STIs to the partner was also found to predict STIs which is similar to a previous report from the USA whereby history of partner STIs was linked to *C. trachomatis* infection. \(^26\) As observed in the current study, most of the STIs were asymptomatic and symptoms occurred when the infection has already passed to the partner. This emphasises the need to consider a policy of laboratory screening for women who opted for IUCD use before insertion of the device in LMICs where these infections are common to avoid unnecessary complications such as tubal factor infertility and chronic PID. The recommended changes are possible in LMICs because most of these infections can be screened by the point of care tests such as those used in the current study. These rapid immunochromatographic tests are less expensive, easy to use (no need of advanced technical skills and equipment) and produce reliable results.

Study limitations

The high prevalence of *C. trachomatis* could be overestimated due to diagnostic technique used in the current study which is less specific as compared to PCR. In addition, *N. gonorrhoea* was not tested because the prevalence of this pathogen has been found to be very low in the study setting.

Conclusion and recommendations

The prevalence of STIs is alarmingly high with *C. trachomatis* being the commonest STI among asymptomatic women opted for IUCD use. There is a paramount need to perform laboratory screening of STIs, especially among women with history of dysuria at least in the past 3 months before seeking placement and partners STIs before IUCD insertion. Further studies to investigate other STIs and outcome of these infections in this population are warranted in this area.

Acknowledgements

The authors acknowledge the assistance provided by administrative officers and workers at the involved hospitals/health centres and the department of Microbiology and Immunology of the Catholic university of Health and allied sciences.

Author contributions

ESM, AK, MMM and SEM participated in the designing of the study. FM, EC and AK participated in data/sample collection. MMM, SEM, HAN and MM participated in laboratory analysis of samples.
PR did pathological analysis of the samples. MMM and SEM analysed and interpreted data. MMM wrote the first draft of the manuscript, SEM, PR, MM and AK did the critical review of the manuscript. All authors approved the last version of the manuscript.

**Availability of data and material**

All data generated/analysed during this study are included in this manuscript. Raw data can be obtained upon request from the director of research and Innovation of the Catholic University of Health and Allied Sciences.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

**Ethical considerations**

Ethical clearance to conduct the study was sought from the joint Catholic University of Health and Allied Sciences/Bugando Medical Centre (CUHAS/BMC) research ethics and review committee (CREC) with ethical clearance number CREC/238/2017 and permission to conduct the study was sought from the hospital and clinic administrations (Regional Medical Officer and Reproductive and Child Health Coordinator). Before being enrolled in the study, participants were given explanations about the study and its objectives and for those who opted to participate were asked to give a written informed consent, and those who were positive to various STIs were given their results and get treated in their family planning attending sites according to the national protocol. Confidentiality was maintained throughout the study.

**Funding**

The author(s) received no financial support for the research, authorship and/or publication of this article.

**Informed consent**

Written informed consent was obtained from the patient(s), before being enrolled in the study.

**ORCID iDs**

Helmut A Nyawale [1][2]  https://orcid.org/0000-0001-6916-6859
Mariam M Mirambo [1][2]  https://orcid.org/0000-0003-2313-3079

**References**

1. Gottlieb SL, Low N, Newman LM, et al. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. *Vaccine* 2014; 32: 1527–1535.
2. Ward H and Rönn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. *Curr Opin HIV AIDS* 2010; 5(4): 305–310.
3. Deutschmann S, Fridolin WB, Kalluvya S, et al. Low prevalence of Neisseria Gonorrhoea Infections and no evidence of resistance against 3rd generation cephalosporins in a cohort of HIV positive patients from a tertiary hospital in Mwanza Tanzania. *8th scientific graduation conference CUHAS, Mwanza, Tanzania, Catholic University of Health and Allied Sciences; 2–3 November 2016*, p. 62.
4. Hokororo A, Kihunrwa A, Hoekstra P, et al. High prevalence of sexually transmitted infections in pregnant adolescent girls in Tanzania: a multi-community cross-sectional study. *Sex Transm Infect* 2015; 91(7): 473–478.
5. Kakaire O, Byamugisha JK, Tumwesigye NM, et al. Prevalence and factors associated with sexually transmitted infections among HIV positive women opting for intrauterine contraception. *PLoS ONE* 2015; 10(4): e0122400.
6. Rivera R and Winfrey W. Long-term safety and effectiveness of copper-releasing intrauterine devices: a case-study. UNDP/UNFPA/WHO/WORLD BANK Special Programme of Research, Development and Research Training in Human Reproduction (HRP). *Citeseer*, 2008, http://apps.who.int/iris/bitstream/10665/69908/WHO_RHR_HRP_08.08_eng.pdf?sequence=1
7. Lake Zone Reproductive and Child Health Report, Ministry of Health, Tanzania; 2014.
8. Lake Zone Reproductive and Child Health Report, Ministry of Health, Tanzania; 2015.
9. Lake Zone Reproductive and Child Health Report, Ministry of Health, Tanzania; 2016.
10. Mohllajee AP, Curtis KM, Flanagan RG, et al. Keeping up with evidence: a new system for WHO’s evidence-based family planning guidance. *Am J Prev Med* 2005; 28(5): 483–490.
11. Mohllajee AP, Curtis KM and Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. *Contraception* 2006; 73(2): 145–153.
12. Mitchell CM, Haick A, Nkwopara E, et al. Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women. *Am J Obstet Gynecol* 2015; 212(5): 611; e1–e9
13. Curtis KM, Tepper NK, Jamieson DJ, et al. Adaptation of the World Health Organization’s selected practice recommendations for contraceptive use for the United States. *Contraception* 2013; 87(5): 513–516.
14. World Health Organization. Selected practice recommendations for contraceptive use. *World Health Organization*, 2005, https://apps.who.int/iris/bitstream/handle/10665/252267/9789241565400-eng.pdf
15. Ghebremichael M. The Syndromic versus Laboratory Diagnosis of Sexually Transmitted Infections in Resource-Limited Settings. *JSRN AIDS* 2014; 2014: 103452.
16. Kosambiya JK, Desai VK, Bhardwaj P, et al. RTI/STI prevalence among urban and rural women of Surat: a community-based study. *Indian J Sex Transm Dis AIDS* 2009; 30(2): 89–93.
17. Standard Treatment Guidelines, Ministry of Health, Tanzania; 2021.
18. National AIDS Control Programme. National Guidelines for the Management of HIV and AIDS. Ministry of Health and Social Welfare. *National AIDS Control Programme*, 2015, https://differentiatedservicelivery.org/Portals/0/adam/Content/NqQGryocrU2RTj58iR37uA/File/NATIONAL_GUIDELINES_FOR_THE_MANAGEMENT_OF_HIV_AND_AIDS_2019.pdf
19. Lapen D, Soule N and Lim S. Papanicolau staining process. *EP1608392B1 Google Patents*, 2007.
20. Ramadhani MY, Mirambo MM, Mbena H, et al. High prevalence of Chlamydia trachomatis infection among infertile
women in Mwanza city, Tanzania: a need to introduce screening and treatment programme. *Sex Transm Infect* 2017; 93: 111–111.

21. Msuya SE, Uriyo J, Hussain A, et al. Prevalence of sexually transmitted infections among pregnant women with known HIV status in northern Tanzania. *Reprod Health* 2009; 6: 4

22. Ng’wamkai G, Msigwa KV, Chengula D, et al. Treponema pallidum infection predicts sexually transmitted viral infections (hepatitis B virus, herpes simplex virus-2, and human immunodeficiency virus) among pregnant women from rural areas of Mwanza region, Tanzania. *BMC Preg Childbirth* 2019; 19: 392

23. Riedner G, Rusizoka M, Hoffmann O, et al. Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya Region, Tanzania. *Sex Transm Infect* 2003; 79(5): 382–387.

24. Gupta PK and Frost JK. Cytopathology and histopathology of the female genital tract in *Trichomonas vaginalis* infection. In: Honigberg BM (ed.) *Trichomonads parasitic in humans*. New York: Springer, 1990, pp. 274–290.

25. Huppert JS, Biro F, Lan D, et al. Urinary symptoms in adolescent females: STI or UTI? *J Adolesc Health* 2007; 40: 418–424.

26. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. *New Engl J Med* 2005; 352: 676–685.